Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 6 Parkinson's papers of 744 | 0.74 |
| pathways Reactome | 2 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 8547
Sealed predictions
- TFG in dopamine neurons, braak+0.85 (p 0.004) → +0.00 (p 1.000)receipt 8553
Swarm cases
receipt 8553: TFG in dopamine neurons, braak
- power
- full sample +0.45 (p 0.060, n 18), 95% CI -0.02 to +0.76. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.49 (p 0.040, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.48 (p 0.043, n 18). not the mix.
- skeptic
- leave-one-out range +0.37 to +0.61, sign flips 0; without severely affected donors +0.45 (p 0.060, n 18). robust.
- cell type
- strongest in OPCs: -0.61 (p 0.0072, n 18) vs +0.45 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TFG in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up TFG · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.07 p 0.790 (needs p < 2.5e-4)
Receipts
loading the receipts